share_log

康方生物(09926.HK)開坦尼治療宮頸癌新適應症上市申請獲內地受理

AASTOCKS ·  Apr 23 20:58

康方生物(09926.HK)公布,國家藥監局(NMPA)已於近期正式受理由公司自主研發的全球首創雙特異性抗體開坦尼(卡度尼利,PD-1/CTLA-4)聯合含鉑化療聯合或不聯合貝伐珠單抗一線治療持續、復發或轉移性宮頸癌的新適應症上市申請(sNDA)。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment